Premium
Delivery of endothelial progenitor cells derived from consomic SS‐13BN/mcwi donor rats reduces diastolic dysfunction in hypertensive SS/MCWi recipients
Author(s) -
Parker Sarah J,
Greene Andrew S.
Publication year - 2011
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.25.1_supplement.661.8
Subject(s) - progenitor cell , diastole , medicine , cd34 , blood pressure , cardiology , endocrinology , diastolic function , endothelial progenitor cell , flow cytometry , arterial stiffness , immunology , stem cell , biology , microbiology and biotechnology
The current study examined whether delivery of bone marrow derived endothelial progenitor cells (EPCs) can reduce diastolic dysfunction in rats with hypertensive heart disease (HHD). EPCs were cultured for two weeks on fibronectin coated plates. Expression of phenotype markers including FLK, CD34, and CD133 was confirmed using flow cytometry. One million EPCs derived from either pre‐hypertensive SS/MCWi rats (N=4) or non‐hypertensive SS‐13BN/mcwi consomic rats (N=4) were injected into the tail vein of hypertensive SS/MCWi recipient rats. A third group received vehicle injections (N=4). Two weeks following EPC delivery left ventricular pressure volume analysis revealed diastolic relaxation (tau), end diastolic pressure, and diastolic stiffness (EDPVR) were reduced in SS‐13BN/mcwi, but not SS/MCWi, EPC treated rats. Mean arterial pressure did not differ between groups. These results indicate that EPCs donated from healthy SS‐13BN/mcwi rats, but not hypertension susceptible SS/MCWi rats, effectively improve diastolic function during HHD. The minimal genetic variability between SS/MCWi and SS‐13BN/mcwi rats will be exploited in future studies to probe underlying molecular mechanisms of EPC therapeutic effect.